Categories Earnings, Health Care
Advaxis’ revenue declines in Q2 as Amgen terminaties collaboration agreement
Advaxis (NASDAQ: ADXS) reported that Q2 revenue decreased to $1.2 million from $1.7 million in the prior year quarter. The 32% decline in revenue was due to the termination of the collaboration agreement with Amgen effective February 2019. Advaxis stock, which closed up 2.94% at $2.80, was trading flat in the after-hours.
Advaxis’ net loss for the second quarter of the fiscal year 2019 was $9.4 million or $1.59 per share compared with a net loss for the second quarter of the fiscal year 2018 of $13.4 million or $4.03 per share.
As of April 30, 2019, Advaxis had cash and cash equivalents of $33.7 million, which includes $9 million in net proceeds from a public offering completed in April.
Also Read: Advaxis shares plummet after reverse stock-split announcement
During the three months ended January 31, 2019, Advaxis recognized approximately $19.4 million of revenue from the Amgen Agreement. In August 2016, Advaxis entered into a global agreement with Amgen for the development and commercialization of ADXS-NEO, preclinical investigational immunotherapy. But Amgen terminated this agreement effective February 8, 2019.
The late-stage biotech company also provided updates on its clinical pipeline. Advaxis expects preliminary data from ADXS-HOT, which is focused on the treatment of most types of non-small cell lung cancers, Phase 1/2 study in the second half of 2019. The company plans to file INDs on two additional HOT constructs within the next nine months.
“In order to ensure we have the appropriate resources to fund our programs, we have taken cost-control measures over the past year. These efforts have resulted in a reduction to our cash burn of more than 50% for the first six months of fiscal year 2019 versus the comparable period last year,” said CEO Kenneth Berlin.
ADXS shares have lost 44% of its value in the last three months and 90% in the past year.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
Comments